Evidence map›Paper›PMID 40235671›Full record

ArticleJournal of analytical methods in chemistry2025

Quantitative Analysis of Muscarinic Antagonist Atropine and Tiotropium in Microvolume Plasma Using Liquid Chromatography-Mass Spectrometry: Application for Pharmacokinetic Studies.

Marilène Trancart, Mylène Penot, Gwladys Meesemaecker, Romain Boffy, Anne-Sophie Hanak, André-Guilhem Calas, Nicolas Taudon

Abstract read
In one paragraph

Article in Journal of analytical methods in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marilène TrancartToxicology and Chemical Risks Department, French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France.ORCID https://orcid.org/0000-0003-3623-0943
Mylène PenotAnalytical Development and Bioanalysis Unit, Platforms and Technological Research Department, French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France.
Gwladys MeesemaeckerToxicology and Chemical Risks Department, French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France.
Romain BoffyAnalytical Development and Bioanalysis Unit, Platforms and Technological Research Department, French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France.
Anne-Sophie HanakToxicology and Chemical Risks Department, French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France.ORCID https://orcid.org/0000-0003-4095-7854
André-Guilhem CalasToxicology and Chemical Risks Department, French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France.ORCID https://orcid.org/0000-0001-7471-8953
Nicolas TaudonAnalytical Development and Bioanalysis Unit, Platforms and Technological Research Department, French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France.ORCID https://orcid.org/0000-0002-8631-1015

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the availability of current resources, the development of medical countermeasures remains crucial in combatting the threat posed by chemical warfare agents, such as organophosphorus compounds (OPs), which are toxic nerve agents requiring rapid medical intervention. Within the available therapeutic arsenal, muscarinic antagonists such as atropine are administered to mitigate the effects of excessive cholinergic system stimulation, which leads to respiratory tract obstruction due to hypersecretions and bronchoconstriction. Tiotropium, an FDA-approved bronchodilator, acts as a muscarinic receptor antagonist and could, therefore, serve as a potential alternative. To assess its potential efficacy in attenuating OP-induced respiratory effects in a murine intoxication model, it was necessary to first characterize its pharmacokinetic properties. A liquid chromatography-mass spectrometry method was developed and validated following ICH M10 guidelines for the quantification of atropine and tiotropium in 10 μL of plasma. The sample pretreatment procedure involved solid-phase extraction. Chromatographic separation was achieved using a fully porous sub 2 μm C18 column. The analysis was completed in just 4 min, with analytes identified and quantified using two selected reaction monitoring transitions. The mean extraction recoveries exceeded 90% for both drugs, and no matrix effect was observed. The lower limits of quantification were 0.5 ng/mL for tiotropium and 1.0 ng/mL for atropine, with an upper limit of 1000 ng/mL. The signal-to-concentration ratio demonstrated recoveries of back-calculated concentrations ranging from 94% to 108% (relative standard deviation (RSD) < 9.0%). Within-run and between-run precisions were both below 8% with accuracies ranging from 87% to 110%. This highly specific and sensitive method has proven useful for analyzing samples from pharmacokinetic studies conducted in mice. Following intraperitoneal administration, the AUC for tiotropium was approximately twice that of atropine, while its Tmax was half as long (4.9 vs. 8.2 min). The terminal half-lives were approximately 7.5 min for tiotropium and 9.8 min for atropine.

Indexed as

atropineLC-MS/MSmedical countermeasureorganophosphorus compoundspharmacokineticsplasmatiotropium

Identifiers

PMID40235671
PMCPMC11999743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.